Protalix BioTherapeutics Inc (DE)

Financials

Total assets 61.56 M73.42 M73.89 M78.49 M82.26 M Total liabilities 29.13 M30.21 M28.68 M28.58 M29.36 M Total equity 32.44 M43.21 M45.21 M49.9 M52.91 M Total liabilities & shareholders' equities 61.56 M73.42 M73.89 M78.49 M82.26 M Total debt ————— Net debt —————

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

PLX

Financials

Protalix BioTherapeutics Inc (DE)

ニュース

Brazil judge overrules decisions suspending changes to meal voucher system

A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)

Pluxee社とEdenred社、好調な業績と見通しを受け株価急騰

Pluxee, Edenred shares jump after upbeat results and outlook

Pluxee 2026年度第1四半期：ブラジルの課題の中でも9%の収益成長

Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds

プロタリックス、制御不能な痛風治療に焦点を当てた2026年戦略を概説

Tuesday’s Insider Activity: Key Execs Make Notable Trades

プロタリックス・バイオセラピューティクスのCEOバシャン・ドロール氏が10万ドル超の株式を購入

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)

プロタリックスとセカルナ、希少腎疾患治療薬開発で提携

Protalix and Secarna partner to develop rare kidney disease treatments